EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery

Rebecca E Andrews iD, Ingrid Jolley, Holly Evans iD, Darren Lath iD, Vanilla Sharma iD, Janet E Brown iD, Michelle A Lawson iD, Andrew D Chantry

British Journal of Haematology · 04.11.2026

DOI: 10.1111/bjh.70903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 04.11.2026. Verfasst von Rebecca E Andrews und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Population Health, and Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weston Park Cancer Charity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloma bone disease (MBD) affects ~90% of myeloma patients, causing pain and reduced quality of life. Current anti‐resorptive treatments retard further destruction but do not repair bone. As new myeloma therapies emerge, understanding their impact on MBD is crucial. This pilot study assessed the feasibility of longitudinally measuring bone recovery in newly diagnosed myeloma patients receiving first‐line therapy (e.g. induction ± autologous stem cell transplant, plus zoledronic acid), as a prelude to formally assessing bone anabolic strategies. Patients underwent whole‐body low‐dose computed tomography imaging and bone marrow biopsy at baseline and 3 months post‐induction/autograft, alongside monthly bone turnover markers. All patients had evidence of partial osteolytic lesion repair, with one patient having resolution of some lesions. Trephine analysis revealed increased trabecular bone volume ( p = 0.003) and osteoblast number ( p < 0.05). However, osteocyte canalicular coverage was significantly reduced ( p < 0.01). Serum C‑terminal telopeptide of type I collagen was suppressed from 2 months ( p < 0.0001), and sclerostin from 3 months ( p = 0.011). This pilot confirms the study design to be feasible. Results suggest that osteolytic lesions have the potential for partial repair, possibly supported by proteasome inhibitors. However, bone lesion resolution is rare, potentially impaired by poor lacunar network connectivity. These data highlight the ongoing need for novel, bone‐targeted therapies to support MBD recovery.

Schlagwörter

Stichwörter der Autor:innen

bone anabolicbone diseasemultiple myelomaosteocytesosteolytic lesionsquality of life

Autor:innen und Institutionen

  • School of Medicine and Population Health, and Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK.
  • Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.

ORCID-Profile: Rebecca E Andrews, Holly Evans, Darren Lath, Vanilla Sharma, Janet E Brown, Michelle A Lawson

Förderung

  • Weston Park Cancer Charity

Zitieren

APA

Andrews, R. E., Jolley, I., Evans, H., Lath, D., Sharma, V., Brown, J. E., Lawson, M. A., & Chantry, A. D. (2026). Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery. British Journal of Haematology. https://doi.org/10.1111/bjh.70903

Vancouver

Andrews RE, Jolley I, Evans H, Lath D, Sharma V, Brown JE, et al. Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery. British Journal of Haematology. 2026. doi:10.1111/bjh.70903

BibTeX
@article{Andrews2026,
  author = {Andrews, Rebecca E and Jolley, Ingrid and Evans, Holly and Lath, Darren and Sharma, Vanilla and Brown, Janet E and Lawson, Michelle A and Chantry, Andrew D},
  title = {Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70903}
}
Kostenlos starten →